文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

清髓性与减低强度预处理在T细胞充足单倍体移植中的比较

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.
PubMed 文献 · Blood Adv · 2019-01-01

该回顾性队列分析纳入1325例接受T细胞充足单倍体移植的AML、ALL或MDS患者,比较清髓性与减低强度预处理对无病生存的影响。18-54岁患者中减低强度方案无病生存更低且复发更高;55-70岁患者中两种方案无病生存无差异,减低强度方案非复发死亡更低。

要点

  • 18-54岁患者清髓性方案无病生存优于减低强度方案
  • 55-70岁患者两种方案无病生存无差异,减低强度非复发死亡更低
  • 清髓性方案应优先用于能耐受的AML、ALL和MDS患者

核心结论

  • 对于AML、ALL和MDS患者,清髓性预处理应优先选择,减低强度方案应保留给无法耐受清髓治疗者。

研究设计与样本

  • 回顾性队列分析纳入1325例接受T细胞充足单倍体移植的 eligible 患者,其中AML 818例、ALL 286例、MDS 221例。
  • 526例接受清髓性方案,799例接受减低强度方案;GVHD预防统一采用移植后环磷酰胺、钙调磷酸酶抑制剂和霉酚酸酯。
  • 主要终点为无病生存,采用Cox回归模型分析预处理强度对移植结局的影响。

主要发现

  • 18-54岁患者中,减低强度方案相比清髓性方案无病生存更低(HR 1.34;42% vs 51%;P=.007),复发更高(HR 1.51;44% vs 33%;P=.001)。
  • 18-54岁患者中,非复发死亡在不同预处理强度间无差异。
  • 55-70岁患者中,无病生存(HR 0.97;37% vs 43%;P=.83)和复发(HR 1.32;42% vs 31%;P=.11)在不同预处理强度间无差异。
  • 55-70岁患者中,减低强度方案非复发死亡更低(HR 0.64;20% vs 31%;P=.02)。

临床怎么用

  • 对18-54岁能耐受的AML、ALL和MDS患者,优先选择清髓性预处理以提高无病生存并降低复发。
  • 对55-70岁患者,可考虑减低强度预处理以降低非复发死亡,无病生存与清髓性方案无差异。

局限性

  • 为回顾性队列分析,非前瞻性研究,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the absence of prospective studies that examine the effect of conditioning regimen intensity after T-cell-replete haploidentical transplant for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS), a retrospective cohort analysis was performed. Of the 1325 eligible patients (AML, n = 818; ALL, n = 286; and MDS, n = 221), 526 patients received a myeloablative regimen and 799 received a reduced-intensity regimen. Graft-versus-host disease prophylaxis was uniform with posttransplant cyclophosphamide, a calcineurin inhibitor, and mycophenolate mofetil. The primary end point was disease-free survival. Cox regression models were built to study the effect of conditioning regimen intensity on transplant outcomes. For patients aged 18 to 54 years, disease-free survival was lower (hazard ratio [HR], 1.34; 42% vs 51%; P = .007) and relapse was higher (HR, 1.51; 44% vs 33%; P = .001) with a reduced-intensity regimen compared with a myeloablative regimen. Nonrelapse mortality did not differ according to regimen intensity. For patients aged 55 to 70 years, disease-free survival (HR, 0.97; 37% vs 43%; P = .83) and relapse (HR, 1.32; 42% vs 31%; P = .11) did not differ according to regimen intensity. Nonrelapse mortality was lower with reduced-intensity regimens (HR, 0.64; 20% vs 31%; P = .02). Myeloablative regimens are preferred for AML, ALL, and MDS; reduced-intensity regimens should be reserved for those unable to tolerate myeloablation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Solomon SR, St Martin A, Shah NN, et al. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv. 2019. PMID: 31582392. doi:10.1182/bloodadvances.2019000627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。